Giancarlo Marone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7108813/publications.pdf

Version: 2024-02-01

277 papers 15,857 citations

71
h-index

25787 108 g-index

283 all docs

283 docs citations

times ranked

283

14548 citing authors

#	Article	IF	CITATIONS
1	Gender dimorphism in IgA subclasses in T2-high asthma. Clinical and Experimental Medicine, 2023, 23, 929-941.	3.6	5
2	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Seminars in Cancer Biology, 2022, 79, 203-216.	9.6	12
3	Neutrophil extracellular traps in cancer. Seminars in Cancer Biology, 2022, 79, 91-104.	9.6	75
4	Neutrophil Extracellular Traps, Angiogenesis and Cancer. Biomedicines, 2022, 10, 431.	3.2	39
5	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Frontiers in Immunology, 2022, 13, 804597.	4.8	27
6	Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions. Cells, 2022, 11, 1720.	4.1	12
7	IgG Autoantibodies Against IgE from Atopic Dermatitis Can Induce the Release of Cytokines and Proinflammatory Mediators from Basophils and Mast Cells. Frontiers in Immunology, 2022, 13, .	4.8	12
8	LPS-mediated neutrophil VEGF-A release is modulated by cannabinoid receptor activation. Journal of Leukocyte Biology, 2021, 109, 621-631.	3.3	25
9	Macrophage-polarizing stimuli differentially modulate the inflammatory profile induced by the secreted phospholipase A2 group IA in human lung macrophages. Cytokine, 2021, 138, 155378.	3.2	13
10	Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2021, 147, 663-676.	2.9	34
11	IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors. Cells, 2021, 10, 145.	4.1	33
12	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	4.0	38
13	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	8
14	The Interplay between the Immune and the Endocannabinoid Systems in Cancer. Cells, 2021, 10, 1282.	4.1	31
15	Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions. Frontiers in Immunology, 2021, 12, 712915.	4.8	26
16	History of the Collegium Internationale Allergologicum: A Very Special Society Devoted to Allergy and Immunology. International Archives of Allergy and Immunology, 2021, 182, 1-9.	2.1	0
17	Human Lung-Resident Macrophages Express and Are Targets of Thymic Stromal Lymphopoietin in the Tumor Microenvironment. Cells, 2021, 10, 2012.	4.1	22
18	IL-3 in the development and function of basophils. Seminars in Immunology, 2021, 54, 101510.	5.6	22

#	Article	IF	CITATIONS
19	Basophil degranulation in response to IgE ligation is controlled by a distinctive circadian clock in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 158-168.	5.7	11
20	Lactate: Fueling the fire starter. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2020, 12, e1474.	6.6	29
21	Hereditary angioedema attack: what happens to vasoactive mediators?. International Immunopharmacology, 2020, 78, 106079.	3.8	7
22	Is There a Role for Basophils in Cancer?. Frontiers in Immunology, 2020, 11, 2103.	4.8	37
23	VEGF-A in Cardiomyocytes and Heart Diseases. International Journal of Molecular Sciences, 2020, 21, 5294.	4.1	121
24	Eosinophils in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1273, 1-28.	1.6	20
25	Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders. Frontiers in Immunology, 2020, 11, 338.	4.8	35
26	Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure. Journal of Clinical Medicine, 2020, 9, 1928.	2.4	21
27	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. International Journal of Molecular Sciences, 2020, 21, 4430.	4.1	20
28	Cardiac Mast Cells: Underappreciated Immune Cells in Cardiovascular Homeostasis and Disease. Trends in Immunology, 2020, 41, 734-746.	6.8	49
29	Mast Cells: Fascinating but Still Elusive after 140 Years from Their Discovery. International Journal of Molecular Sciences, 2020, 21, 464.	4.1	25
30	Anaplastic Thyroid Cancer Cells Induce the Release of Mitochondrial Extracellular DNA Traps by Viable Neutrophils. Journal of Immunology, 2020, 204, 1362-1372.	0.8	45
31	Metabolic Checkpoints in Rheumatoid Arthritis. Frontiers in Physiology, 2020, 11, 347.	2.8	41
32	Basophils in Tumor Microenvironment and Surroundings. Advances in Experimental Medicine and Biology, 2020, 1224, 21-34.	1.6	30
33	HIV gp120 Induces the Release of Proinflammatory, Angiogenic, and Lymphangiogenic Factors from Human Lung Mast Cells. Vaccines, 2020, 8, 208.	4.4	17
34	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. International Journal of Molecular Sciences, 2019, 20, 3934.	4.1	69
35	Heterogeneity of Human Mast Cells With Respect to MRGPRX2 Receptor Expression and Function. Frontiers in Cellular Neuroscience, 2019, 13, 299.	3.7	71
36	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	8

#	Article	IF	Citations
37	What Is the Cardiac Impact of Chemotherapy and Subsequent Radiotherapy in Lymphoma Patients?. Antioxidants and Redox Signaling, 2019, 31, 1166-1174.	5.4	21
38	Future Needs in Mast Cell Biology. International Journal of Molecular Sciences, 2019, 20, 4397.	4.1	83
39	Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. International Journal of Molecular Sciences, 2019, 20, 4413.	4.1	140
40	Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opinion on Investigational Drugs, 2019, 28, 931-940.	4.1	68
41	Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019. International Archives of Allergy and Immunology, 2019, 179, 247-261.	2.1	75
42	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
43	Immunosuppressive therapy with rituximab in common variable immunodeficiency. Clinical and Molecular Allergy, 2019, 17, 9.	1.8	36
44	Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer. International Journal of Molecular Sciences, 2019, 20, 2106.	4.1	145
45	Superantigenic Activation of Human Cardiac Mast Cells. International Journal of Molecular Sciences, 2019, 20, 1828.	4.1	39
46	Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy. Journal of Allergy and Clinical Immunology, 2019, 143, 1067-1076.	2.9	90
47	Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. International Journal of Molecular Sciences, 2019, 20, 834.	4.1	48
48	The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma. Frontiers in Pharmacology, 2019, 10, 1387.	3.5	104
49	Prostaglandin D ₂ receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. Expert Opinion on Investigational Drugs, 2019, 28, 73-84.	4.1	50
50	Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Current Medicinal Chemistry, 2019, 26, 2801-2822.	2.4	6
51	Human mast cells and basophils—How are they similar how are they different?. Immunological Reviews, 2018, 282, 8-34.	6.0	124
52	Roles of neutrophils in cancer growth and progression. Journal of Leukocyte Biology, 2018, 103, 457-464.	3.3	113
53	Eosinophils: The unsung heroes in cancer?. Oncolmmunology, 2018, 7, e1393134.	4.6	184
54	Severe Aortic Valve Regurgitation in Relapsing Polychondritis. Journal of Clinical Rheumatology, 2018, 24, 109-111.	0.9	1

#	Article	IF	Citations
55	Cancer Inflammation and Cytokines. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028662.	5. 5	175
56	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. Lancet Oncology, The, 2018, 19, 1545-1546.	10.7	16
57	The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. Frontiers in Immunology, 2018, 9, 2601.	4.8	74
58	Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency. Frontiers in Immunology, 2018, 9, 1721.	4.8	19
59	Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study. Orphanet Journal of Rare Diseases, 2018, 13, 115.	2.7	24
60	Innate effector cells in angiogenesis and lymphangiogenesis. Current Opinion in Immunology, 2018, 53, 152-160.	5.5	92
61	Potential involvement of neutrophils in human thyroid cancer. PLoS ONE, 2018, 13, e0199740.	2.5	54
62	Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Frontiers in Immunology, 2018, 9, 1595.	4.8	133
63	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology, 2018, 9, 167.	2.8	118
64	N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor. Frontiers in Immunology, 2018, 9, 574.	4.8	16
65	Neutrophils Involvement in Human Thyroid Cancer. Journal of Allergy and Clinical Immunology, 2018, 141, AB122.	2.9	0
66	Hereditary angioedema: the plasma contact system out of control: comment. Journal of Thrombosis and Haemostasis, 2018, 16, 2347-2348.	3.8	3
67	Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Annals of the Rheumatic Diseases, 2018, 77, 1773-1781.	0.9	52
68	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	2.4	99
69	Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital. Current Pharmaceutical Biotechnology, 2018, 19, 728-733.	1.6	14
70	Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy. Current Pharmaceutical Biotechnology, 2018, 19, 734-741.	1.6	12
71	Mast cells in rheumatoid arthritis: friends or foes?. Autoimmunity Reviews, 2017, 16, 557-563.	5.8	52
72	Cellular subtype expression and activation of CaMKII regulate the fate of atherosclerotic plaque. Atherosclerosis, 2017, 256, 53-61.	0.8	16

#	Article	lF	Citations
73	Lipopolysaccharide-Elicited TSLPR Expression Enriches a Functionally Discrete Subset of Human CD14+CD1c+ Monocytes. Journal of Immunology, 2017, 198, 3426-3435.	0.8	26
74	Hereditary Angioedema with Normal C1 Inhibitor: An Italian Case Series. Journal of Allergy and Clinical Immunology, 2017, 139, AB231.	2.9	0
75	Histamine Release from Mast Cells and Basophils. Handbook of Experimental Pharmacology, 2017, 241, 121-139.	1.8	70
76	The Role of Omalizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg‧trauss): Comment on the Article by Jachiet et al. Arthritis and Rheumatology, 2017, 69, 868-870.	5.6	3
77	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	4.5	186
78	Controversial role of mast cells in skin cancers. Experimental Dermatology, 2017, 26, 11-17.	2.9	69
79	Evaluation of vaccination safety in children with mastocytosis. Pediatric Allergy and Immunology, 2017, 28, 93-95.	2.6	28
80	FRI0030â \in Synovial mast cells identify patients with a severe phenotype in a cohort of dmard naÃve patients with early rheumatoid arthritis., 2017,,.		0
81	GM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity. Frontiers in Immunology, 2017, 7, 680.	4.8	38
82	Are Mast Cells MASTers in Cancer?. Frontiers in Immunology, 2017, 8, 424.	4.8	243
83	Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils. Frontiers in Immunology, 2017, 8, 443.	4.8	65
84	Bidirectional Mast Cell–Eosinophil Interactions in Inflammatory Disorders and Cancer. Frontiers in Medicine, 2017, 4, 103.	2.6	88
85	Abstract SY06-01: Tumor-associated myelomonocytic cells as therapeutic targets. , 2017, , .		0
86	A Unique Case of Angioedema With Anti-C1 Inhibitor Antibodies and Normal C1 Inhibitor Levels. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 111-112.	1.3	6
87	FRI0043â€Synovial Mast Cells Correlate with Local and Systemic Inflammation and Are Functionally Associated with Ectopic Lymphoid Structures in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 441.3-442.	0.9	0
88	Stress and Psychological Factors in the Variable Clinical Phenotype of Hereditary Angioedema in Children: A Pilot Study. Pediatric, Allergy, Immunology, and Pulmonology, 2016, 29, 6-12.	0.8	15
89	Prophylactic treatment with plasmaâ€derived C1 inhibitor in idiopathic nonâ€histaminergic angioedema. Pediatric Allergy and Immunology, 2016, 27, 658-659.	2.6	5
90	Elevated plasma levels of vascular permeability factors in C1 inhibitorâ€deficient hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 989-996.	5.7	46

#	Article	IF	Citations
91	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	5.1	141
92	Are Basophils and Mast Cells Masters in HIV Infection?. International Archives of Allergy and Immunology, 2016, 171, 158-165.	2.1	24
93	The immune network in thyroid cancer. Oncolmmunology, 2016, 5, e1168556.	4.6	88
94	Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death and Differentiation, 2016, 23, 1542-1554.	11.2	154
95	Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. Journal of Cardiac Failure, 2016, 22, 449-458.	1.7	60
96	T follicular helper (T _{fh}) cells in normal immune responses and in allergic disorders. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1086-1094.	5.7	82
97	Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Annals of Allergy, Asthma and Immunology, 2016, 117, 394-398.	1.0	78
98	FRIOO36â€Meta-Immunological Profiling of Patients with Behçet's Disease Reveals Novel Biomarkers of Disease Activity, Progression and Response To Therapy: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 438.3-439.	0.9	0
99	High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet Journal of Rare Diseases, 2016, 11, 133.	2.7	15
100	Reply. Arthritis and Rheumatology, 2016, 68, 769-770.	5.6	3
101	Immunometabolic biomarkers of inflammation in BehÃSet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens. Clinical and Experimental Immunology, 2016, 184, 197-207.	2.6	28
102	Differential impact of high and low penetrance <i>TNFRSF1A</i> gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	3.3	15
103	The Proteomic Landscape of Human ExÂVivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity, 2016, 44, 406-421.	14.3	201
104	Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. Journal of Asthma, 2016, 53, 201-206.	1.7	50
105	Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. Journal of Leukocyte Biology, 2016, 99, 531-540.	3.3	98
106	Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. European Journal of Pharmacology, 2016, 778, 146-151.	3.5	95
107	The oncolytic virus <i>dl</i> 922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget, 2016, 7, 1500-1515.	1.8	58
108	Effect Of $\hat{l}\pm 2$ -Adrenergic Agonists And Antagonists On Cytokine Release From Human Lung Macrophages Cultured In Vitro. Translational Medicine @ UniSa, 2016, 15, 67-73.	0.5	7

#	Article	IF	Citations
109	Hereditary angiooedema and psychological stress: an exploratory study. Clinical and Translational Allergy, 2015, 5, O6.	3.2	1
110	FRT – FONDATION RENE TOURAINE. Experimental Dermatology, 2015, 24, 803-820.	2.9	0
111	THU0024â€Human Mast Cells Stimulated with IL-33 and Immune Complexes Down-Regulate Monocyte Activation in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 201.2-201.	0.9	O
112	ILâ€3 synergises with basophilâ€derived ILâ€4 and ILâ€13 to promote the alternative activation of human monocytes. European Journal of Immunology, 2015, 45, 2042-2051.	2.9	37
113	Ability of Interleukinâ€33– and Immune Complex–Triggered Activation of Human Mast Cells to Downâ€Regulate Monocyteâ€Mediated Immune Responses. Arthritis and Rheumatology, 2015, 67, 2343-2353.	5.6	50
114	Tumor-Associated Mast Cells in Thyroid Cancer. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	48
115	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. BioMed Research International, 2015, 2015, 1-14.	1.9	34
116	Home Therapy with Plasma-Derived C1 Inhibitor: A Strategy to Improve Clinical Outcomes and Costs in Hereditary Angioedema. International Archives of Allergy and Immunology, 2015, 166, 259-266.	2.1	17
117	Immune-metabolic profiling of anorexic patients reveals an anti-oxidant and anti-inflammatory phenotype. Metabolism: Clinical and Experimental, 2015, 64, 396-405.	3.4	37
118	Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway. Oncogene, 2015, 34, 5175-5186.	5.9	176
119	Angiogenesis and lymphangiogenesis in inflammatory skin disorders. Journal of the American Academy of Dermatology, 2015, 73, 144-153.	1.2	141
120	Upregulation of the $\langle i \rangle N \langle i \rangle$ -Formyl Peptide Receptors in Scleroderma Fibroblasts Fosters the Switch to Myofibroblasts. Journal of Immunology, 2015, 194, 5161-5173.	0.8	33
121	Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacological Research, 2015, 102, 184-191.	7.1	97
122	Lymph node fine needle aspiration cytology in systemic mastocytosis: cytological features with ancillary tests and literature review. Cytopathology, 2015, 26, 31-37.	0.7	5
123	The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene, 2015, 34, 3826-3838.	5.9	69
124	Immune Cells as a Source and Target of Angiogenic and Lymphangiogenic Factors. Chemical Immunology and Allergy, 2014, 99, 15-36.	1.7	33
125	Leptin modulates autophagy in human CD4+CD25â^ conventional T cells. Metabolism: Clinical and Experimental, 2014, 63, 1272-1279.	3.4	45
126	Histamine Receptors and Antihistamines: From Discovery to Clinical Applications. Chemical Immunology and Allergy, 2014, 100, 214-226.	1.7	42

#	Article	IF	Citations
127	Basophils: Historical Reflections and Perspectives. Chemical Immunology and Allergy, 2014, 100, 172-192.	1.7	55
128	Basophils and Skin Disorders. Journal of Investigative Dermatology, 2014, 134, 1202-1210.	0.7	33
129	Immunopharmacological modulation of mast cells. Current Opinion in Pharmacology, 2014, 17, 45-57.	3.5	32
130	Mutational Spectrum of the C1 Inhibitor Gene in a Cohort of Italian Patients with Hereditary Angioedema: Description of Nine Novel Mutations. Annals of Human Genetics, 2014, 78, 73-82.	0.8	34
131	IgE and ILâ€33â^'mediated triggering of human basophils inhibits TLR4â^'induced monocyte activation. European Journal of Immunology, 2014, 44, 3045-3055.	2.9	32
132	P21 ―Evaluation of modifications in SCORMA Index and grading in the followâ€up of a pediatric population with mastocytosis. Clinical and Translational Allergy, 2014, 4, P76.	3.2	0
133	Human heart as a shock organ in anaphylaxis. Allergo Journal International, 2014, 23, 60-66.	2.0	28
134	Simplexide Induces CD1d-Dependent Cytokine and Chemokine Production from Human Monocytes. PLoS ONE, 2014, 9, e111326.	2.5	8
135	Tumor associated macrophages and neutrophils in tumor progression. Journal of Cellular Physiology, 2013, 228, 1404-1412.	4.1	346
136	Preliminaries. Chemical Immunology and Allergy, 2013, 99, I-XII.	1.7	20
137	Helicobacter Pylori HP(2–20) Induces Eosinophil Activation and Accumulation in Superficial Gastric Mucosa and Stimulates VEGF-α and TGF-β Release by Interacting with Formyl-Peptide Receptors. International Journal of Immunopathology and Pharmacology, 2013, 26, 647-662.	2.1	17
138	FRI0035â€Expression and functions of vascular endothelial growth factor and angiopoietin receptors in human synovial mast cells. Annals of the Rheumatic Diseases, 2013, 71, 321.2-321.	0.9	0
139	Expression and function of Angiopoietins and their tie receptors in human basophils and mast cells. Journal of Biological Regulators and Homeostatic Agents, 2013, 27, 827-39.	0.7	33
140	Angiogenesis, Lymphangiogenesis and Atopic Dermatitis. Chemical Immunology and Allergy, 2012, 96, 50-60.	1.7	33
141	IMMUNOPATHOGENESIS OF PSORIASIS AND PSORIATIC ARTHRITIS AND PHARMACOLOGICAL PERSPECTIVES. Reumatismo, 2011, 59, 28-39.	0.9	4
142	Modulation of Mast Cell and Basophil Functions by Benzene Metabolites. Current Pharmaceutical Design, 2011, 17, 3830-3835.	1.9	12
143	Benzene Metabolites Inhibit the Release of Proinflammatory Mediators and Cytokines from Human Basophils. International Journal of Immunopathology and Pharmacology, 2010, 23, 737-744.	2.1	10
144	Mast cells have a protumorigenic role in human thyroid cancer. Oncogene, 2010, 29, 6203-6215.	5.9	190

#	Article	IF	Citations
145	Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 946-958.	5.7	113
146	Antiapoptotic Seminal Vesicle Protein IV Induces Histamine Release from Human FclμRI+ Cells. International Archives of Allergy and Immunology, 2010, 151, 318-330.	2.1	0
147	Production of Vascular Endothelial Growth Factors from Human Lung Macrophages Induced by Group IIA and Group X Secreted Phospholipases A2. Journal of Immunology, 2010, 184, 5232-5241.	0.8	111
148	The role of mast cell-derived secreted phospholipases A2 in respiratory allergy. Biochimie, 2010, 92, 588-593.	2.6	21
149	<i>Helicobacter pylori</i> Hp(2–20) Promotes Migration and Proliferation of Gastric Epithelial Cells by Interacting with Formyl Peptide Receptors In Vitro and Accelerates Gastric Mucosal Healing In Vivo. Journal of Immunology, 2009, 183, 3761-3769.	0.8	60
150	Inhibition of Secretory Phospholipase A ₂ -Induced Cytokine Production in Human Lung Macrophages by Budesonide. International Archives of Allergy and Immunology, 2009, 150, 144-155.	2.1	21
151	Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. Journal of Allergy and Clinical Immunology, 2009, 123, 1142-1149.e5.	2.9	186
152	Lung mast cells are a source of secreted phospholipases A2. Journal of Allergy and Clinical Immunology, 2009, 124, 558-565.e3.	2.9	63
153	Allergy and the cardiovascular system. Clinical and Experimental Immunology, 2008, 153, 7-11.	2.6	131
154	Role of Superallergens in Allergic Disorders. , 2007, 93, 195-213.		46
155	Protein Fv: An Endogenous Immunoglobulin Superantigen and Superallergen. , 2007, 93, 58-76.		16
156	Differentiation of monocytes into macrophages induces the upregulation of histamine H1 receptor. Journal of Allergy and Clinical Immunology, 2007, 119, 472-481.	2.9	60
157	Risk assessment in anaphylaxis: Current and future approaches. Journal of Allergy and Clinical Immunology, 2007, 120, S2-S24.	2.9	237
158	Basophil's secrets revealed by flow cytometry. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1025-1027.	5.7	8
159	Superallergens: a new mechanism of immunologic activation of human basophils and mast cells. Inflammation Research, 2006, 55, S25-S27.	4.0	13
160	Expression and Functions of the Vascular Endothelial Growth Factors and Their Receptors in Human Basophils. Journal of Immunology, 2006, 177, 7322-7331.	0.8	114
161	Mast cells and basophils: friends as well as foes in bronchial asthma?. Trends in Immunology, 2005, 26, 25-31.	6.8	101
162	Role of Human Mast Cells and Basophils in Bronchial Asthma. Advances in Immunology, 2005, 88, 97-160.	2.2	57

#	Article	IF	Citations
163	Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 2. Journal of Immunology, 2004, 173, 5739-5748.	0.8	100
164	Basophils Infiltrate Human Gastric Mucosa at Sites of <i>Helicobacter pylori</i> Infection, and Exhibit Chemotaxis in Response to <i>H. pylori-</i> derived Peptide Hp(2–20). Journal of Immunology, 2004, 172, 7734-7743.	0.8	63
165	Differential modulation of mediator release from human basophils and mast cells by mizolastine. Clinical and Experimental Allergy, 2004, 34, 241-249.	2.9	17
166	Superallergens: a novel mechanism of IgE-mediated activation of human basophils and mast cells. Clinical and Experimental Allergy Reviews, 2004, 4, 64-75.	0.3	5
167	The human heart as a shock organ in anaphylaxis. Novartis Foundation Symposium, 2004, 257, 133-49; discussion 149-60, 276-85.	1.1	15
168	Protein Fv Produced during Viral Hepatitis Is an Endogenous Immunoglobulin Superantigen Activating Human Heart Mast Cells. International Archives of Allergy and Immunology, 2003, 132, 336-345.	2.1	24
169	The histamine-cytokine network in allergic inflammation. Journal of Allergy and Clinical Immunology, 2003, 112, S83-S88.	2.9	73
170	Immunoglobulin Superantigen Protein L Induces IL-4 and IL-13 Secretion from Human FclμRI+Cells Through Interaction with thel [®] Light Chains of IgE. Journal of Immunology, 2003, 170, 1854-1861.	0.8	91
171	Secretory Phospholipases A ₂ as Multivalent Mediators of Inflammatory and Allergic Disorders. International Archives of Allergy and Immunology, 2003, 131, 153-163.	2.1	45
172	Role of Human Heart Mast Cells in Immunologic and Inflammatory Mechanisms Underlying Cardiovascular Disorders. Developments in Cardiovascular Medicine, 2003, , 185-198.	0.1	1
173	HIV-1 Envelope gp41 Peptides Promote Migration of Human FcεRI+ Cells and Inhibit IL-13 Synthesis Through Interaction with Formyl Peptide Receptors. Journal of Immunology, 2002, 169, 4559-4567.	0.8	39
174	Histamine H1-receptor-mediated release of preformed mediators and cytokines and airway remodelling. Clinical and Experimental Allergy Reviews, 2002, 2, 89-94.	0.3	3
175	Pharmacological modulation of human mast cells and basophils. Clinical and Experimental Allergy, 2002, 32, 1682-1689.	2.9	14
176	Dysregulation of the lgE/FcÏμRI network in HIV-1 infection. Journal of Allergy and Clinical Immunology, 2001, 107, 22-30.	2.9	26
177	Human mast cells and basophils in HIV-1 infection. Trends in Immunology, 2001, 22, 229-232.	6.8	49
178	Envelope gp120 of HIV-1 binds to and activates human basophils. Rendiconti Lincei, 2001, 12, 117-131.	2.2	0
179	Role of human FcepsilonRI+ cells in HIV-1 infection. Immunological Reviews, 2001, 179, 128-138.	6.0	24
180	Italian immunology well but hoping to do better. Nature, 2001, 413, 771-771.	27.8	0

#	Article	IF	CITATIONS
181	Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 2001, 25, 603-625.	0.8	1,020
182	Treatment of mastocytosis: pharmacologic basis and current concepts. Leukemia Research, 2001, 25, 583-594.	0.8	52
183	Histamine-Induced Activation of Human Lung Macrophages. International Archives of Allergy and Immunology, 2001, 124, 249-252.	2.1	35
184	Are Mast Cells MASTers in HIV-1 Infection?. International Archives of Allergy and Immunology, 2001, 125, 89-95.	2.1	29
185	Histamine Induces Exocytosis and IL-6 Production from Human Lung Macrophages Through Interaction with H1 Receptors. Journal of Immunology, 2001, 166, 4083-4091.	0.8	135
186	The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. Aids, 2000, 14, 931-938.	2.2	28
187	Immunological Interactions between Human Eosinophils and Cardiac Mast Cells. , 2000, 76, 118-133.		10
188	HIV-1 gp120 Induces IL-4 and IL-13 Release from Human Fc $\hat{l}\mu$ RI+ Cells Through Interaction with the VH3 Region of IgE. Journal of Immunology, 2000, 164, 589-595.	0.8	157
189	Bacterial Immunoglobulin Superantigen Proteins A and L Activate Human Heart Mast Cells by Interacting with Immunoglobulin E. Infection and Immunity, 2000, 68, 5517-5524.	2.2	88
190	Tat Protein Is an HIV-1-Encoded β-Chemokine Homolog That Promotes Migration and Up-Regulates CCR3 Expression on Human FcεRI+ Cells. Journal of Immunology, 2000, 165, 7171-7179.	0.8	67
191	Secretory Phospholipases A2 Induce \hat{I}^2 -Glucuronidase Release and IL-6 Production from Human Lung Macrophages. Journal of Immunology, 2000, 164, 4908-4915.	0.8	88
192	Human Mast Cells and Basophils in Immune Responses to Infectious Agents. , 2000, , 397-418.		8
193	Mechanisms of IgE elevation in HIV-1 infection. Critical Reviews in Immunology, 2000, 20, 477-96.	0.5	12
194	The antiâ€igE/antiâ€FcεRIα autoantibody network in allergic and autoimmune diseases. Clinical and Experimental Allergy, 1999, 29, 17-27.	2.9	122
195	Immunological modulation of human cardiac mast cells. Neurochemical Research, 1999, 24, 1195-1202.	3.3	28
196	Endogenous Superallergen Protein Fv Interacts with the V _H 3 Region of IgE to Induce Cytokine Secretion from Human Basophils. International Archives of Allergy and Immunology, 1999, 118, 197-199.	2.1	20
197	Tryptase-Chymase Double-Positive Human Mast Cells Express the Eotaxin Receptor CCR3 and Are Attracted by CCR3-Binding Chemokines. American Journal of Pathology, 1999, 155, 1195-1204.	3.8	220
198	Stem cell factor is localized in, released from, and cleaved by human mast cells. Journal of Immunology, 1999, 163, 2799-808.	0.8	71

#	Article	IF	Citations
199	Antiinflammatory effects of oxatomide. Journal of Investigational Allergology and Clinical Immunology, 1999, 9, 207-14.	1.3	11
200	In situ characterization of mast cells in the frog Rana esculenta. Cell and Tissue Research, 1998, 292, 151-162.	2.9	37
201	Immunopharmacology of human mast cells and basophils. International Journal of Clinical and Laboratory Research, 1998, 28, 12-22.	1.0	30
202	Asthma: recent advances. Trends in Immunology, 1998, 19, 5-9.	7.5	60
203	Stem Cell Factor in Mast Cells and Increased Mast Cell Density in Idiopathic and Ischemic Cardiomyopathy. Circulation, 1998, 97, 971-978.	1.6	228
204	Tacrolimus Ointment for Atopic Dermatitis. New England Journal of Medicine, 1998, 339, 1788-1789.	27.0	17
205	Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation Antihistamines. Molecular Pharmacology, 1998, 54, 113-121.	2.3	130
206	Human Cardiac Mast Cells and Their Role in Severe Allergic Reactions. , 1998, , 237-257.		6
207	Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. Journal of Immunology, 1998, 161, 5647-55.	0.8	54
208	Molecular and Cellular Biology of Mast Cells and Basophils. International Archives of Allergy and Immunology, 1997, 114, 207-217.	2.1	105
209	Characterization of Platelet-activating Factor Acetylhydrolase in Human Bronchoalveolar Lavage. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 94-100.	5.6	62
210	Heterogeneous effects of protamine on human mast cells and basophils. British Journal of Anaesthesia, 1997, 78, 724-730.	3.4	20
211	Eosinophil Granule Proteins Are Selective Activators of Human Heart Mast Cells. International Archives of Allergy and Immunology, 1997, 113, 200-202.	2.1	23
212	Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy. Inflammation Research, 1997, 46, 31-32.	4.0	40
213	Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcÉ>RI+ cells. Clinical and Experimental Allergy, 1997, 27, 559-567.	2.9	62
214	Milestones in the biology and pharmacology of histamine H ₁ â€receptor antagonists. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 7-13.	5.7	9
215	Metabolic and hemodynamic effects of peptide leukotriene C4 and D4 in man. International Journal of Clinical and Laboratory Research, 1997, 27, 178-184.	1.0	50
216	Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. Arthritis and Rheumatism, 1997, 40, 469-478.	6.7	40

#	Article	IF	Citations
217	Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalaninea~†, a~†a~†, a~…, a~…a~ Journal of Allergy and Clinical Immunology, 1996, 152-164.	2 83	59
218	Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator releaseâ€. Journal of Allergy and Clinical Immunology, 1996, 97, 838-850.	2.9	72
219	Oxatomide Inhibits the Release of Proinflammatory Mediators from Human Basophils and Mast Cells. International Archives of Allergy and Immunology, 1996, 111, 23-29.	2.1	21
220	Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization. Arthritis and Rheumatism, 1996, 39, 1222-1233.	6.7	79
221	Eosinophil granule proteins activate human heart mast cells. Journal of Immunology, 1996, 157, 1219-25.	0.8	74
222	Immunological characterization and functional importance of human heart mast cells. Immunopharmacology, 1995, 31, 1-18.	2.0	100
223	The antineoplastic bryostatins affect human basophils and mast cells differently. Blood, 1995, 85, 1272-1281.	1.4	28
224	Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool Journal of Experimental Medicine, 1995, 182, 1181-1190.	8.5	86
225	Human Heart Mast Cells: A Definitive Case of Mast Cell Heterogeneity. International Archives of Allergy and Immunology, 1995, 106, 386-393.	2.1	75
226	Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. Journal of Immunology, 1995, 154, 2855-65.	0.8	123
227	Biology, diagnosis and therapy of mastocytosis. Chemical Immunology and Allergy, 1995, 62, 1-21.	1.7	1
228	Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils. European Journal of Clinical Pharmacology, 1993, 45, S17-S20.	1.9	18
229	Mechanisms of activation of human mast cells and basophils by general anaesthetic drugs. Annales Francaises D'Anesthesie Et De Reanimation, 1993, 12, 116-125.	1.4	64
230	Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells. Journal of Pharmacology and Experimental Therapeutics, 1993, 267, 1375-85.	2.5	23
231	In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. Journal of Immunology, 1993, 151, 5563-73.	0.8	34
232	Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells. Journal of Immunology, 1993, 151, 5685-98.	0.8	33
233	Human Basophil/Mast Cell Releasability. Anesthesiology, 1992, 77, 932-940.	2.5	82
234	Anti-Inflammatory Effect of Cyclosporin A on Human Skin Mast Cells. Journal of Investigative Dermatology, 1992, 98, 800-804.	0.7	132

#	Article	IF	Citations
235	Anti-Inflammatory Effect of FK-506 on Human Skin Mast Cells. Journal of Investigative Dermatology, 1992, 99, 723-728.	0.7	135
236	Selective activation of human mast cells by general anesthetics. Agents and Actions, 1992, 36, C191-C194.	0.7	7
237	Heterogeneity of human basophils and mast cells in response to muscle relaxants. Agents and Actions, 1992, 36, C195-C198.	0.7	0
238	Inhibition of histamine release from human FclµRI+ cells by nimesulide. Agents and Actions, 1992, 36, C311-C314.	0.7	7
239	Activation of human mast cells and basophils by general anaesthetic drugs. Monographs in Allergy, 1992, 30, 54-73.	0.2	9
240	Heterogeneity of Human Mast Cells and Basophils in Response to Muscle Relaxants. Anesthesiology, 1991, 74, 1078-1086.	2.5	86
241	Human Basophil Releasability. VIII. Increased Basophil Releasability in Patients with Scleroderma. Arthritis and Rheumatism, 1991, 34, 1289-1296.	6.7	25
242	FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. Journal of Immunology, 1991, 146, 2374-81.	0.8	88
243	Characterization of the anti-inflammatory effect of FK-506 on human mast cells. Journal of Immunology, 1991, 147, 4278-85.	0.8	57
244	Nonspecific histamine-releasing properties of general anesthetic drugs. Clinical Reviews in Allergy, 1991, 9, 269-280.	1.0	13
245	Human Basophil Releasability: VI. Changes in Basophil Releasability in Patients with Allergic Rhinitis or Bronchial Asthma. The American Review of Respiratory Disease, 1990, 142, 1108-1111.	2.9	63
246	Adenosine receptors of human leukocytes—II. Biochemical Pharmacology, 1990, 40, 1963-1973.	4.4	22
247	Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. Journal of Immunology, 1990, 144, 3891-7.	0.8	102
248	Protein L. A bacterial Ig-binding protein that activates human basophils and mast cells. Journal of Immunology, 1990, 145, 3054-61.	0.8	65
249	Human Basophil/Mast Cell Releasability: V. Functional Comparisons of Cells Obtained from Peripheral Blood, Lung Parenchyma, and Bronchoalveolar Lavage in Asthmatics. The American Review of Respiratory Disease, 1989, 139, 1375-1382.	2.9	100
250	IgG Anti-IgE from Atopic Dermatitis Induces Mediator Release from Basophils and Mast Cells. Journal of Investigative Dermatology, 1989, 93, 246-252.	0.7	88
251	Human basophil/mast cell releasability. VII. Heterogeneity of the effect of adenosine on mediator secretion. Life Sciences, 1989, 45, 1745-1754.	4.3	23
252	The role of mast cell and basophil activation in human allergic reactions. The European Respiratory Journal Supplement, 1989, 6, 446s-455s.	0.8	0

#	Article	IF	Citations
253	Cardiovascular and Metabolic Effects of Peptide Leukotrienes in Man. Annals of the New York Academy of Sciences, 1988, 524, 321-333.	3.8	42
254	Adenosine Potentiates Mediator Release from Human Lung Mast Cells. The American Review of Respiratory Disease, 1988, 138, 1143-1151.	2.9	149
255	Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. Biochemical Pharmacology, 1987, 36, 13-20.	4.4	72
256	Effects of histamine on coronary hemodynamics in humans: Role of H1and H2receptors. Journal of the American College of Cardiology, 1987, 10, 1207-1213.	2.8	48
257	Mechanism of activation of human basophils by Staphylococcus aureus Cowan 1. Infection and Immunity, 1987, 55, 803-809.	2.2	34
258	Human Basophil Releasability. II. Changes in Basophil Releasability in Patients with Atopic Dermatitis. Journal of Investigative Dermatology, 1986, 87, 19-23.	0.7	61
259	The Wiskott-Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes. British Journal of Haematology, 1986, 62, 737-745.	2.5	25
260	Effect of activation of the H1 receptor on coronary hemodynamics in man Circulation, 1986, 73, 1175-1182.	1.6	87
261	Human basophil releasability. III. Genetic control of human basophil releasability. Journal of Immunology, 1986, 137, 3588-92.	0.8	32
262	Activation of human basophils by Staphylococcus aureus Cowan I. II. Alternative F(abâ \in 2)-mediated mechanism. Agents and Actions, 1985, 16, 359-362.	0.7	5
263	Evidence for an adenosine A2/Ra receptor on human basophils. Life Sciences, 1985, 36, 339-345.	4.3	34
264	Chemical mediators and the human heart. Progress in Biochemical Pharmacology, 1985, 20, 38-54.	0.2	5
265	Inhibition of IgE-Mediated Histamine Release from Human Basophils and Mast Cells by Fenoterol. International Archives of Allergy and Immunology, 1984, 74, 356-361.	2.1	41
266	Cardiovascular Effects of Histamine Infusion in Man. Journal of Cardiovascular Pharmacology, 1983, 5, 531-537.	1.9	79
267	Activation of human basophils by staphylococcal protein A. I. The role of cyclic AMP, arachidonic acid metabolites, microtubules and microfilaments. Clinical and Experimental Immunology, 1982, 50, 661-8.	2.6	27
268	Possible role of phospholipase A2 in triggering histamine secretion from human basophils in vitro. Clinical Immunology and Immunopathology, 1981, 20, 231-239.	2.0	51
269	IgE-Mediated Histamine Release from Human Basophils: Differences between Antigen E- and Anti-IgE-Induced Secretion. International Archives of Allergy and Immunology, 1981, 65, 339-348.	2.1	60
270	An inhibitor of lipoxygenase inhibits histamine release from human basophils. Clinical Immunology and Immunopathology, 1980, 17, 117-122.	2.0	50

#	ARTICLE	IF	CITATIONS
271	Adenosine receptor on human basophils: modulation of histamine release. Journal of Immunology, 1979, 123, 1473-7.	0.8	69
272	Effects of arachidonic acid and its metabolites on antigen-induced histamine release from human basophils in vitro. Journal of Immunology, 1979, 123, 1669-77.	0.8	116
273	Hepatic Erythropoietin: Enhanced Production in Anephric Rats with Hyperplasia of Kupffer Cells. British Journal of Haematology, 1976, 32, 105-112.	2.5	23
274	Pure Red Cell Aplasia: Studies on an IgG Serum Inhibitor Neutralizing Erythropoietin. British Journal of Haematology, 1975, 30, 411-417.	2.5	117
275	Independence of Iron Absorption From the Rate of Erythropoiesis. Blood, 1974, 44, 353-358.	1.4	23
276	Renal Mechanisms Underlying Cyclic AMP Action on Erythropoiesis. British Journal of Haematology, 1973, 25, 393-398.	2.5	7
277	Differential Effects of Alarmins on Human and Mouse Basophils. Frontiers in Immunology, $0,13,.$	4.8	10